Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shailender Bhatia

Medical Oncology Seattle, WA Medical Doctor

NPI 1225041791 CMS profile 10408

825 Eastlake Ave E, Mailstop G4-830, Seattle, WA 98109

Open in the dashboard

General payments

$107,055

43 records reported · program years 2019–2025

Research payments

$1,211

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,388,946 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Shailender Bhatia of Seattle, WA is reported in the CMS Open Payments database as having received $107,055 across 43 general payments and $1,211 in research payments paid to them. Separately, studies naming them as principal investigator received $7,388,946 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,625 17
2025 Research $443 1
2024 General $15,448 6
2024 Research $768 2
2023 General $6,900 3
2022 General $157 1
2021 General $4,864 3
2020 General $5,850 2
2019 General $45,211 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shailender Bhatia
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Shailender Bhatia were reported at $28,625. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Shailender Bhatia Medical Oncology median Middle half National median
2019 $45,211 $968 $140–$6,658 $163
2020 $5,850 $747 $102–$5,891 $114
2021 $4,864 $430 $50–$4,098 $132
2022 $157 $812 $127–$4,907 $149
2023 $6,900 $957 $144–$5,248 $160
2024 $15,448 $1,042 $149–$5,650 $164
2025 $28,625 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. EMD Serono, Inc. $48,160 7 payments
  2. Genzyme Corporation $17,380 7 payments
  3. Regeneron Pharmaceuticals, Inc. $13,208 4 payments
  4. Merck Sharp & Dohme Corporation $8,975 11 payments
  5. E.R. Squibb & Sons, L.L.C. $7,710 4 payments
  6. Incyte Corporation $4,999 1 payment
  7. Regeneron Healthcare Solutions, Inc. $3,400 2 payments
  8. Immunocore Limited $2,400 1 payment
  9. Surefire Medical, Inc. $432 3 payments
  10. Clinigen Inc $392 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $53,201 14 payments
  2. Consulting Fee $33,097 9 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,054 4 payments
  4. Honoraria $2,400 1 payment
  5. Food and Beverage $1,303 15 payments
Products named General payments · program years 2019–2025
  1. LIBTAYO Oncology $17,380 7 payments
  2. OPDIVO $3,900 2 payments
  3. LIBTAYO Oncology $3,502 3 payments
  4. KIMMTRAK $2,400 1 payment
  5. TRINAV INFUSION SYSTEM $432 3 payments
  6. Proleukin Metastatic Renal Cell Carcinoma or Melanoma $247 2 payments
  7. Proleukin Metastatic Renal Cell Carcinoma or Melanoma $145 1 payment
  8. Bavencio $30 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,211 3 payments

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$26,733

Medicare's payments for the services billed

Medicare patients

117

Average age 73

Services billed

335

39 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 34%
Ischemic heart disease 26%
Cancer 22%
Diabetes 21%
Depression 19%
Atrial fibrillation 17%
Chronic kidney disease 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record